As of close of business last night, InMed Pharmaceuticals Inc’s stock clocked out at $0.38, up 5.25% from its previous closing price of $0.36. In other words, the price has increased by $+0.0190 from its previous closing price. On the day, 2170772 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of INM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.58 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 21 ’24 when HULL ANDREW bought 37,500 shares for $0.39 per share. The transaction valued at 14,625 led to the insider holds 38,258 shares of the business.
ADAMS ERIC A bought 41,600 shares of INM for $14,922 on Feb 20 ’24. The President & CEO now owns 43,959 shares after completing the transaction at $0.36 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INM now has a Market Capitalization of 2.18M and an Enterprise Value of -6.19M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.23 while its Price-to-Book (P/B) ratio in mrq is 0.17. Its current Enterprise Value per Revenue stands at -1.13 whereas that against EBITDA is 0.97.
Stock Price History:
Over the past 52 weeks, INM has reached a high of $2.08, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.3736, while the 200-Day Moving Average is calculated to be 0.6996.
Shares Statistics:
It appears that INM traded 183.03K shares on average per day over the past three months and 182.31k shares per day over the past ten days. A total of 3.33M shares are outstanding, with a floating share count of 3.27M. Insiders hold about 1.80% of the company’s shares, while institutions hold 24.16% stake in the company. Shares short for INM as of Feb 15, 2024 were 138.25k with a Short Ratio of 0.76, compared to 70.78k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.28% and a Short% of Float of 2.28%.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $1.49M. It ranges from a high estimate of $1.49M to a low estimate of $1.49M. As of the current estimate, InMed Pharmaceuticals Inc’s year-ago sales were $1.03M, an estimated increase of 44.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.79M, a decrease of -22.60% less than the figure of $44.10% in the same quarter last year. There is a high estimate of $1.79M for the next quarter, whereas the lowest estimate is $1.79M.
A total of 1 analysts have provided revenue estimates for INM’s current fiscal year. The highest revenue estimate was $5.42M, while the lowest revenue estimate was $5.42M, resulting in an average revenue estimate of $5.42M. In the same quarter a year ago, actual revenue was $4.14M, up 31.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.77M in the next fiscal year. The high estimate is $6.77M and the low estimate is $6.77M. The average revenue growth estimate for next year is up 24.90% from the average revenue estimate for this year.
